Abbott Laboratories (ABT)vsBio-Rad Laboratories Inc (BIO-B)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
BIO-B
Bio-Rad Laboratories Inc
$268.55
0.00%
HEALTHCARE · Cap: $6.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 1644% more annual revenue ($44.33B vs $2.54B). ABT leads profitability with a 14.7% profit margin vs -85.2%. BIO-B appears more attractively valued with a PEG of 1.21. ABT earns a higher WallStSmart Score of 51/100 (C-).
ABT
Buy51
out of 100
Grade: C-
BIO-B
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Intrinsic value data unavailable for BIO-B.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
ROE of -27.5% — below average capital efficiency
Revenue declined 4.2%
Earnings declined 83.0%
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : BIO-B
The strongest argument for BIO-B centers on Price/Book, Debt/Equity. PEG of 1.21 suggests the stock is reasonably priced for its growth.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : BIO-B
The primary concerns for BIO-B are Return on Equity, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ABT profiles as a value stock while BIO-B is a turnaround play — different risk/reward profiles.
BIO-B carries more volatility with a beta of 0.94 — expect wider price swings.
ABT is growing revenue faster at 4.4% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (51/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Bio-Rad Laboratories Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?